At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Pre-Mkt 05-19 04:36:42 EDT
16.44
-1.11
-6.32%
盘前16.65
+0.21+1.28%
04:13 EDT
High17.54Low16.11Vol933.77K
Open17.45D1 Closing17.55Amplitude8.17%
Mkt Cap1.21BTradable Cap646.33MTotal Shares73.62M
T/O15.45MT/O Rate2.38%Tradable Shares39.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  05-16 22:35
LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherap Is Maintained at Buy by Needham
Dow Jones  ·  05-12
MoonLake Immunotherap Is Maintained at Buy by Needham
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  05-12
Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25
THOMSON REUTERS  ·  05-12
MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
TIPRANKS  ·  05-12
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
TIPRANKS  ·  05-11
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential
MoonLake Q1 net loss widens 71.9% to $69.7 million
Reuters  ·  05-11
MoonLake Q1 net loss widens 71.9% to $69.7 million
MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-11
MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
TIPRANKS  ·  05-11
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  05-11
MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.
MoonLake Immunotherapeutics Q1 Net Loss Widens
MT Newswires Live  ·  05-11
MoonLake Immunotherapeutics Q1 Net Loss Widens
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
TIPRANKS  ·  05-11
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
MoonLake says aligned with FDA on submission plans for sonelokimab
TIPRANKS  ·  05-11
MoonLake says aligned with FDA on submission plans for sonelokimab
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
TIPRANKS  ·  05-11
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
MoonLake says FDA backs sonelokimab HS BLA plan, filing set for September 2026
Reuters  ·  05-10
MoonLake says FDA backs sonelokimab HS BLA plan, filing set for September 2026
Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission
Reuters  ·  05-10
Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission
MoonLake Immunotherapeutics - FDA Accepts Mira and Vela-Teen Trial Data for Sonelkimab Bla Submission
THOMSON REUTERS  ·  05-10
MoonLake Immunotherapeutics - FDA Accepts Mira and Vela-Teen Trial Data for Sonelkimab Bla Submission
MoonLake Immunotherapeutics Announces Positive Outcome From Its Final Pre-Bla Meeting With the U.S. FDA and Reports First Quarter 2026 Financial Results
THOMSON REUTERS  ·  05-10
MoonLake Immunotherapeutics Announces Positive Outcome From Its Final Pre-Bla Meeting With the U.S. FDA and Reports First Quarter 2026 Financial Results
MoonLake Immunotherapeutics - Bla Submission for Sonelkimab in Hs Planned for End of September 2026
THOMSON REUTERS  ·  05-10
MoonLake Immunotherapeutics - Bla Submission for Sonelkimab in Hs Planned for End of September 2026
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
GlobeNewswire  ·  05-10
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--